A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
This is a phase 1 study (the first phase in testing a drug, to see how safe the study drug
is) to find the best dose of investigational drug trametinib in patients with solid cancers
and varying levels of hepatic (liver) dysfunction.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society